Acute Pyelonephritis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The acute pyelonephritis market size was valued at USD 340.36 million in 2025 and is estimated to grow from USD 356.53 million in 2026 to reach USD 449.64 million by 2031, at a CAGR of 4.75% during the forecast period (2026-2031). This report is Segmented by Product Type (Antibiotics [Fluoroquinolones and More], Diagnostic Products, Supportive Care), Healthcare Setting (Outpatient Settings and More), Distribution Channel (Hospital Pharmacies and More), Patient Type (Adult Women, Adult Men, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Acute Pyelonephritis Market Trends and Insights

Rising Burden of Complicated Urinary Tract Infections

The acute pyelonephritis market benefits from a growing clinical burden of complicated urinary tract infections. A 2025 analysis of Global Burden of Disease data reported that urinary tract infection incidence is increasing. It projected an age-standardized incidence rate of 6,486.39 per 100,000 by 2050. The same publication described a 43.5% increase from the 2022 level to the 2050 projection. These figures indicate continued demand for diagnosis and treatment when infections progress to complicated disease. Complicated cases carry higher treatment needs than uncomplicated urinary infections. The United States recorded more than 3 million complicated urinary tract infection episodes each year. Inpatient pyelonephritis cohorts had mortality ranging from 0% to 11%. When bacteremia occurred, 30-day mortality reached as high as 50%. These clinical risks support prompt diagnosis and appropriate antimicrobial treatment.

The acute pyelonephritis market also includes patients who receive complex treatment outside the hospital. Outpatient parenteral antibiotic therapy allows selected patients to receive intravenous medicines without a full inpatient stay. That care model still requires prescriptions, dispensing, clinical monitoring, and follow-up. It therefore maintains demand for intravenous therapies even when a patient is not admitted. The pathway changes where care occurs, rather than removing the need for treatment.

Increasing Multidrug-Resistant Gram-Negative Infections

Multidrug-resistant gram-negative infections are increasing the need for treatment options that address resistant organisms. Third-generation cephalosporin-resistant and carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii are identified as priority pathogens. A 2024 Lancet review discussed the global importance of multidrug-resistant gram-negative bacterial infections. Resistant infections can make standard empiric treatment less successful. This creates demand for culture-guided care and agents active against resistant pathogens. The acute pyelonephritis market consequently depends more on diagnostic-supported prescribing.

The acute pyelonephritis market is affected because resistance changes both the treatment choice and the diagnostic pathway. Prescribers need susceptibility data when common options are no longer reliable. Resistance can increase demand for beta-lactam and beta-lactamase inhibitor combinations in confirmed cases. The February 2024 FDA approval of EXBLIFEP, cefepime and enmetazobactam, for this treatment need. Its role is to illustrate the movement toward resistance-targeted therapy.

Antimicrobial Resistance and Reduced Empiric Treatment Success

Antimicrobial resistance can increase demand for new drugs while reducing treatment efficiency. Resistance can cause an empiric regimen to fail before a culture result guides a replacement. This can lead to repeat visits, rehospitalization, and additional antibiotic use. The 2025 IDSA guideline states that fluoroquinolone resistance exceeds the threshold for empiric use across all United States regions. The guideline therefore affects a treatment class long used in outpatient acute pyelonephritis care.

The economic effect of an unsuccessful treatment pathway can be substantial. A 2026 cohort study reported mean hospital costs of USD 35,082 for intravenous-to-outpatient parenteral antibiotic therapy transitions. The same study reported USD 27,905 for intravenous-to-oral transitions. Patients who completed intravenous therapy in hospital had mean costs of USD 53,359. These cost differences create pressure to identify patients who can transition to oral therapy safely. The acute pyelonephritis market is affected by this focus on efficient care delivery. Resistance also narrows the role of older generic antibiotics. It can shift prescriptions toward patented treatments with activity against resistant organisms. However, a narrower choice of usable agents can limit broad volume growth in the acute pyelonephritis market. The result is a more complex treatment pattern rather than a uniform expansion in every antibiotic class. Effective diagnostics and stewardship remain important in managing that constraint.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Rapid Urinary Pathogen and Resistance Testing
• Development of Oral Step-Down Therapies for Resistant Infections
• Antibiotic Stewardship and Shorter Treatment Duration

Segment Analysis

Antibiotics held 89.31% of the acute pyelonephritis market share in 2025. This concentration reflects the need for systemic antimicrobial therapy in acute pyelonephritis. The category includes fluoroquinolones, cephalosporins, carbapenems, aminoglycosides, and beta-lactam and beta-lactamase inhibitor combinations. The broad range of classes allows treatment to be adjusted for infection severity and resistance findings. Beta-lactam and beta-lactamase inhibitor combinations are moving quickly within antibiotics because resistant gram-negative infections require additional options.

Utebzi entered the United States treatment setting in June 2026 as an oral carbapenem option for adults with complicated urinary tract infections. Carbapenems continue to have an important hospital role despite stewardship pressure. Aminoglycosides also remain relevant in multidrug-resistant settings. A 2024 review discussed their high urinary concentrations, broad gram-negative activity, and limited collateral microbiome disruption compared with beta-lactams and fluoroquinolones. Supportive care products remain tied to hydration and renal monitoring in higher-acuity cases.

Diagnostic products are forecast to expand at 6.58% CAGR from 2026 to 2031. This growth rate is above the overall acute pyelonephritis market size CAGR of 4.75% over the same period. Urinalysis and susceptibility testing form the largest diagnostic area. Molecular systems can shorten the usual 48-72 hour culture-to-result process. The result is a faster basis for deciding whether standard therapy remains appropriate. A 2024 clinical evaluation of the Sysmex and Astrego PA-100 phenotypic antimicrobial susceptibility testing system reported 85% categorical agreement for ciprofloxacin. The study reported a turnaround time below 45 minutes. Blood tests and blood culture remain important in high-risk cases. Bacteremia occurred in 27-38% of hospitalized complicated urinary tract infection bacteremia episodes. These clinical needs maintain demand for pathogen identification beyond routine urine testing.

Outpatient settings held 55.24% of revenue in 2025 and are forecast to grow at 6.22% CAGR through 2031. This reflects care redesign rather than a reduced burden of serious disease. Selected patients can receive intravenous treatment through outpatient parenteral antibiotic therapy without a full hospital admission. The approach supports treatment access while reducing time in an inpatient bed. It also requires clear clinical selection and follow-up arrangements. A Scottish pathway published in 2024 lists outpatient intravenous gentamicin, amikacin, ceftriaxone, and ertapenem for adults with febrile pyelonephritis who do not need hospitalization. The outpatient model remains supported by more recent care pathways and practice guidance.

Acute and inpatient settings remain necessary for severe presentations. The research states that 20% of pyelonephritis presentations require inpatient admission. Inpatient care remains relevant for patients with sepsis, obstruction, older age, or significant comorbidities. Those patients may need intravenous treatment, monitoring, and more extensive diagnostic work. Cost pressures favor a transition when it is clinically appropriate. The 2026 study reported mean inpatient costs of USD 53,359 for cases completed entirely with intravenous therapy in hospital. This is higher than the reported cost for intravenous-to-oral transitions. Hospital stewardship programs and payment models can reinforce the move toward outpatient parenteral therapy or oral transition pathways. The setting mix will therefore depend on clinical risk, treatment response, and the availability of follow-up care.

Complete Report Scope:

• By Product Type
  • Antibiotics
    • Fluoroquinolones
    • Cephalosporins
    • Carbapenems
    • Aminoglycosides
    • Beta-Lactam/Beta-Lactamase Inhibitor Combinations
    • Other Antibiotics
  • Diagnostic Products
    • Urinalysis and Susceptibility Testing
    • Blood Tests and Blood Culture
    • Other Diagnostic Products
  • Supportive Care Products
• By Healthcare Setting
  • Outpatient Settings
  • Acute and Inpatient Settings
  • Other Healthcare Setting
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
  • Specialty Pharmacies
  • Other Distribution Channels
• By Patient Type
  • Adult Women
  • Adult Men
  • Pediatric Patients
  • Other Patient Types
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of revenue in 2025. The region benefits from advanced diagnostic infrastructure, high treatment costs, and recent approvals of new antimicrobial options. The United States is the main contributor within North America. GSK describes more than 3 million complicated urinary tract infection episodes and more than USD 6 billion in annual costs in the United States. These care costs support interest in effective treatment and transition pathways.

FDA QIDP and Fast Track designations as supportive of development for drugs targeting resistant gram-negative pathogens. Canada and Mexico add volume under different formulary and generic-use structures. North American demand therefore includes both hospital-based treatment and outpatient transition options. Europe is the second-largest regional area. Germany, the United Kingdom, France, Italy, and Spain are its main contributing countries. European prescribing is shaped by antimicrobial guidelines and the WHO Access-Watch-Reserve framework. The Scottish outpatient pathway supports community administration of selected intravenous treatments for eligible pyelonephritis patients. A 2025 practice guideline also reported successful treatment for more than 94% of patients in a retrospective cohort of 6,120 outpatient parenteral antimicrobial therapy cases.

Asia-Pacific is forecast to expand at 7.25% CAGR through 2031. This makes it the fastest-growing regional component of the acute pyelonephritis market size. Shionogi received National Medical Products Administration approval for cefiderocol in China in January 2026 for complicated urinary tract infections, including pyelonephritis. This provides a new treatment option in a major Asia-Pacific country. The Middle East and Africa as divided between higher adoption in GCC markets and limited access in Sub-Saharan Africa and South Africa. South America, especially Brazil and Argentina, was associated with higher health expenditure and high ESBL prevalence. Access to novel drugs remains uneven across lower-resource settings. Generic antibiotics consequently continue to have a substantial role. Regional performance will depend on testing access, reimbursement, and availability of resistance-targeted medicines.

List of Companies Covered in this Report:

• Abbott Laboratories
• Allecra Therapeutics GmbH
• Astellas Pharma
• Aurobindo Pharma
• Bayer
• bioMérieux
• Cipla
• Danaher
• Roche
• GlaxoSmithKline
• Iterum Therapeutics plc
• Johnson & Johnson
• Lupin
• Melinta Therapeutics, LLC
• Merck
• Paratek Pharmaceuticals
• Pfizer
• QIAGEN
• Shionogi & Co., Ltd.
• Spero Therapeutics, Inc.
• Sun Pharmaceuticals Industries
• Sysmex
• Thermo Fisher Scientific
• Venatorx Pharmaceuticals, Inc.
• Venus Remedies Limited
• Wockhardt

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support